NIAMS. NIAID, pharmaceutical companies and nonprofit organizations have formed the Accelerating Medicines Partnership (AMP) Rheumatoid Arthritis – Lupus Program to develop new ways of identifying and validating promising biological targets for diagnostics and drug development. An overview of the AMP Rheumatoid Arthritis – Lupus Program and its three research phases and a listing of the academic groups collaborating on the work are available.
The overall aim of the rheumatoid arthritis collaborative project is to collect synovial tissue from research biopsies and elective surgical procedures and blood specimens from individuals with RA to perform analytics for molecular deconstruction of RA and to compare with clinical phenotype and disease course.
The RA clinical sites include:Barts and the London School of Medicine and Dentistry
The primary objective of the lupus collaborative project is to analyze kidney, blood, urine, and skin specimens from subjects with lupus nephritis and from control subjects to achieve molecular deconstruction of disease mechanisms. Specifically, the objectives are to identify disease-specific pathways that could serve as targets for novel therapies, to correlate cellular and molecular patterns in the kidney with clinical response to standard of care, and to identify blood, urine, and skin surrogates for renal profiles.
For both rheumatoid arthritis and lupus analyses the technical sites for tissue dissociation and analysis include Brigham and Women’s Hospital, and Broad Institute
The Foundation for the NIH facilitated the partnership of the academic, pharma, and non-profit organizations.
Download the AMP Data Set Summary
|Study||Study Information||Data Counts||PIs||Publications||Pubmed ID||DOI|
Methods for high-dimensional analysis of cells dissociated from cyropreserved synovial tissue.
Donlin LT, Rao DA, Wei K, Slowikowski K, McGeachy MJ, Turner JD, Meednu N, Mizoguchi F, Gutierrez-Arcelus M, Lieb DJ, Keegan J, Muskat K, Hillman J, Rozo C, Ricker E, Eisenhaure TM, Li S, Browne EP, Chicoine A, Sutherby D, Noma A; Accelerating Medicines Partnership RA/SLE Network, Nusbaum C, Kelly S, Pernis AB, Ivashkiv LB, Goodman SM, Robinson WH, Utz PJ, Lederer JA, Gravallese EM, Boyce BF, Hacohen N, Pitzalis C, Gregersen PK, Firestein GS, Raychaudhuri S, Moreland LW, Holers VM, Bykerk VP, Filer A, Boyle DL, Brenner MB, Anolik JH Arthritis Res Ther. 2018 Jul 11;20(1):139. doi: 10.1186/s13075-018-1631-y.;
Relevant study: SDY999
Identification of Three Rheumatoid Arthritis Disease Subtypes by Machine Learning Integration of Synovial Histologic Features and RNA Sequencing Data.
Orange DE, Agius P, DiCarlo EF, Robine N, Geiger H, Szymonifka J, McNamara M, Cummings R, Andersen KM, Mirza S, Figgie M, Ivashkiv LB, Pernis AB, Jiang CS, Frank MO, Darnell RB, Lingampali N, Robinson WH, Gravallese E; Accelerating Medicines Partnership in Rheumatoid Arthritis and Lupus Network, Bykerk VP, Goodman SM, Donlin LT. Arthritis Rheumatol. 2018 May;70(5):690-701. doi: 10.1002/art.40428. Epub 2018 Apr 2.
Relevant study: SDY1299
Single cell RNA sequencing to dissect the molecular heterogeneity in lupus nephritis.
Der E, Ranabothu S, Suryawanshi H, Akat KM, Clancy R, Morozov P, Kustagi M, Czuppa M, Izmirly P, Belmont HM, Wang T, Jordan N, Bornkamp N, Nwaukoni J, Martinez J, Goilav B, Buyon JP, Tuschl T, Putterman C. JCI Insight. 2017 May 4;2(9). pii: 93009. doi: 10.1172/jci.insight.93009.
Relevant study: SDY997